The purpose of this study was comparing dose-volume histogram (DVH)-based plan verification methods for volumetric modulated arc therapy (VMAT) pretreatment QA. We evaluated two 3D dose reconstruction systems: ArcCHECK-3DVH system (Sun Nuclear corp.) and Varian dynalog-based dose reconstruction (DBDR) system, developed in-house.
| INTRODUCTION
Recently, volumetric modulated arc radiotherapy (VMAT) has become a routine technique in many facilities. Although this technique improves the conformity of dose distribution to PTV and reduces the impact on OARs, its use in a complex dose distribution with a sharp gradient necessitates patient-specific quality assurance (QA). The most frequently employed method for QA has been comparison of the calculated and measured doses in a phantom. Particularly, the point dose on an ion chamber and planar dose distribution on a film are usually measured. In general, gamma analysis has been used to compare measured and calculated dose distributions in a commercial radiation treatment planning system (TPS). 1 However, these conventional patient-specific QA procedures are very time consuming for the clinical staff. In addition, some previous studies showed that gamma analysis cannot directly predict the actual patient dose. 2, 3 To tackle these problems, some independent dose reconstruction methods have been proposed to evaluate patient dose-volume his- system delivers a 3D patient dose that can be reconstructed using 3DVH software from the original TPS plan and ArcCHECK measurement data. The reconstructed dose from this system could be compared with the TPS-calculated dose using 3D gamma and DVH dose index analyses. The accuracy of the system has already been investigated in several studies. [4] [5] [6] Another method is machine log file-based dose reconstruction.
Some have reported the use of log files generated by multi-leaf collimator (MLC) controller as a tool for DVH-based dose verification for patient-specific QA of intensity-modulated radiotherapy (IMRT). 7 In VMAT, on the other hand, machine log files that contain other dynamic parameters (gantry angles and cumulative MU) are generated from a Linac control system. Some studies demonstrated dose reconstruction methods that modify TPS plan data using delivered parameters from these log files and recalculate by TPS dose calculation algorithm. The 3DVH-HS dose morphing is recommended for detecting even very small deviations from ideal behavior.
2.C | In-house dynalog-based dose reconstruction system
In VMAT, two sets of Varian dynalog were generated. One was beam delivery dynalog, which was created by the Linac console and contained information delivered from the dynamic beam (e.g., the actual cumulative dose delivered (MU) versus the actual gantry angle); these parameters were only recorded for each control point. The other log was the MLC dynalog, which was created by the MLC controller. The file was separately generated and acquired every 50 ms for the MLC banks A and B. Details of the MLC dynalog have been described elsewhere. 13 In this study, dynalog-based dose reconstruction (DBDR) was performed by an in-house software and Eclipse TPS. 
2.D | Validation of the in-house DBDR system
Before using the in-house DBDR system for patient-specific QA, the system was validated by a method similar to the one used by Juan et al. to check for programming errors. 7 For a baseline plan (Singlearc prostate VMAT, 2.6 Gy/1 Fr), nine MLC error plans were generated (Table 1) . To measure the absolute dose at the center of the phantom, these plans were delivered by a 15-MV X-ray beam of Varian 23EX with a 120 millennium MLC to an ArcCHECK phantom with a customized acrylic plug that was holding a 0.6-cc PTW 30013
Farmer ionization chamber. Absolute isocenter dose was used to evaluate the accuracy of the in-house DBDR system.
2.E | Workflow and Analysis of DVH-based QA
A schematic design of this study is shown in Fig. 1 . First, ArcCHECK QA plans were created from the original plans for all patients. Second, ArcCHECK measurement (ArcCHECK was calibrated with 200 MU with a 10 9 10 cm 2 field size at a gantry angle 0°before plan irradiation) was performed on all plans; simultaneously, the Varian dynalog data sets that contained the actual delivered parameters (leaf positions, gantry angles, and cumulative MUs) were acquired from the Linac control system. Thereafter, the delivered 3D patient dose was reconstructed by 3DVH software and in-house DBDR system. We evaluated the differences between the TPS-calculated dose and the reconstructed dose using whole body 3D gamma passing rates (3%/ 3 mm, 2%/2 mm, and 1%/1 mm with global normalization, threshold 10%) and DVH dose index analysis. For the DVH analysis of the prostate case, PTV doses (mean dose, D95% and maximum dose) and rectum wall and bladder wall dose (mean dose, V35 and V55) were evaluated. For the whole neck case, PTV doses (D50% and maximum dose), brainstem and spinal cord doses (maximum dose), and parotids dose (mean dose and maximum dose) were evaluated. For the esophagus case, PTV doses (D50% and maximum dose), spinal cord dose (maximum dose), and lungs doses (mean dose and V20) were evaluated. In addition, we calculated the clinically effective confidence limit values for each DVH dose index using the following eq. (1) Confidence limit ¼ jDD mean j þ 1:96 DD SD (1) where DD mean was the average dose differences between the TPS-calculated dose and the reconstructed dose and DD SD was the standard deviation. All 3D analyses were performed in 3DVH software ver.3.2.
| RESULTS

3.A | Validation of the in-house DBDR System
The results of validation of the in-house DBDR system are summarized in Table 1 . Nine MLC error plans (#1~9) were created for baseline plan (#0), and irradiated to 0.6-cc Farmer ion chamber in center of ArcCHECK phantom. The values for the error/baseline ratio showed a significant positive correlation (R 2 = 0.986; P < 0.01) between the measurement values and DBDR values. Although we validated the system using MLC error plans without accounting for gantry angle and MU errors, we confirmed that the system could work correctly in dynamic irradiation.
3.B | Analysis of DVH-based QA
Before 3D reconstructed dose analysis, we evaluated the 2D planar dose that was measured by ArcCHECK for all patients using SNC T for all patients (3%/3 mm, global normalization, threshold 10%)),
indicating that conventional 2D patient-specific QA was mostly successful. shown. For 3DVH methods, there were differences observed between the TPS-calculated and reconstructed doses. In addition, a difference between 3DVH-HS and 3DVH-NS was observed. On the other hand, using the in-house DBDR method, there were little differences between the TPS-calculated and reconstructed doses. Table 2 shows the whole-body 3D gamma passing rates for all patient. The average whole-body 3D gamma passing rates (3%/ 3 mm) were 99.1 AE 0.6%, 99.7 AE 0.3%, and 100.0 AE 0.1% for 3DVH-HS, 3DVH-NS, and DBDR, respectively. The results of DVHbased QA for each DVH dose index and the confidence limits are summarized in Table 3 . These dose differences varied for each reconstruction method and DVH dose index. The confidence limits in this study were within 9.67% for 3DVH-HS, 9.72% for 3DVH-NS, and 3.64% for DBDR. Table 2 .
| DISCUSSION
In this study, before comparing two DVH-based QA methods that were the ArcCHECK-3DVH system and the in-house DBDR system, we validated the in-house DBDR system using MLC error plans,
showing that the system was a well-developed DVH-based QA tool.
Thereafter, we compared these methods using 3D analysis, showing that the ArcCHECK-3DVH system had some differences from the in-house DBDR system.
The accuracy of the ArcCHECK-3DVH system has been validated by several authors, such as Olch et al., who used ion chamber and EDR2 film, 4 and Watanabe et al., who used BANG3 polymer gel dosimeter. 5 Furthermore, using error-induced plans, Kadoya et al.
reported that 3DVH-NS was better than 3DVH-HS in terms of dose reconstruction accuracy. 6 These findings were consistent with our results in the present study. Particularly, compared with 3DVH-HS, the 3DVH-NS had a dose distribution that was in good agreement with the TPS-calculated dose distribution (Fig. 2) . In addition, 3DVH
methods use the ACPDP model parameters optimized in other facilities beforehand. Therefore, for DVH dose index analysis, the systematic errors for a specific DVH parameter were observed in 3DVH methods than DBDR (Fig. 3) . In addition, we evaluated the method under the heterogeneous treatment sites (Figs. 5 and 6 ). The 3DVH reconstructed dose is calculated by dose ratio map between ACPDP and TPS based on the homogeneity cylindrical phantom. 12 Therefore, the effect of heterogeneity is not considered under the dose reconstruction, resulting in a change of the dose distribution especially in the heterogeneous region such as paranasal sinus and lungs.
T A B L E 3 DVH dose index analysis between TPS-calculated dose and each reconstructed dose (average AE SD, %), and confidence limits for all DVH parameters calculated by the eq. (1) 3DVH-HS, High Sensitivity dose morphing in 3DVH software; 3DVH-NS, Normal Sensitivity dose morphing in 3DVH software; DBDR, in-house Dynalog-based dose reconstruction method.
The dose difference of the in-house DBDR system from the TPS-calculated dose was smaller than that of the ArcCHECK-3DVH
system. This result was congruent with the results of previous studies. 11 The improvement in dose reconstruction accuracy may have been due to identical dose calculation algorithm for both treatment planning and DBDR. That is, the errors caused by the different F I G . 3. Dose differences in parameter mean dose (D mean ) and maximum dose (D max ) for the target volume (PTV) between TPS-calculated dose and each reconstructed dose, for all prostate patients. The DBDR dose showed good agreement to the reference TPS-calculated dose in all DVH parameters, while 3DVH doses showed some difference to the reference dose in a specific DVH parameter such as maximum dose. dose calculation algorithms were zero in log file-based dose reconstruction method. Therefore, in contrast to the 3DVH method, the dose distribution using DBDR method was good agreement to the TPS-calculated dose even under the heterogeneous situation.
Although machine log file-based dose reconstruction may be useful for patient-specific QA, only few hospitals use this method. Further evidence is needed to implement this method into clinical practice.
In this study, the measured dose with the ArcCHECK and the machine log file were acquired only once for each plan, respectively. This is a limitation of the study and the reproducibility of each reconstruction method remained to be evaluated in further study. important to simplify the procedures to reduce the burden on clinical staff. Therefore, our results will serve to help medical physicists to understand the reliability of once measurement of each dose reconstructed method.
Some previous studies on large planning data (700 cases of Head and Neck VMAT, and 73 cases of prostate VMAT) were reported for the MatriXX-COMPASS system, one of the DVH-based QA methods of using MGDR. 14, 15 On the other hand, there have been no largescale studies on ArcCHECK-3DVH system and machine log-file based dose reconstruction. In this study, we investigated the accuracy of different dose reconstruction methods on 15 prostate, 4
head and neck, and 4 esophagus VMAT patients. We calculated the confidence limit for each DVH-based QA metrics (Table 3 ). In terms of tolerance for DVH-based patient-specific QA, Visser et al. suggested that action levels may clearly distinguish the role of the medical physicist and radiation oncologist during the QA procedure. 14 Our results indicate that these confidence limits may be used by medical physicists.
| CONCLUSION
The two DVH-based QA methods that we evaluated in this study had different dose reconstruction accuracies. Although with some residual dose reconstruction errors, these two methods can be clinically used as effective tools for DVH-based QA for VMAT.
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